Free Trial
NASDAQ:AVBP

ArriVent BioPharma (AVBP) Stock Price, News & Analysis

ArriVent BioPharma logo
$20.76 -0.35 (-1.64%)
Closing price 07/3/2025 01:04 PM Eastern
Extended Trading
$20.76 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About ArriVent BioPharma Stock (NASDAQ:AVBP)

Key Stats

Today's Range
$20.01
$21.20
50-Day Range
$18.75
$25.42
52-Week Range
$15.47
$36.37
Volume
286,026 shs
Average Volume
227,762 shs
Market Capitalization
$710.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00
Consensus Rating
Buy

Company Overview

ArriVent BioPharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

AVBP MarketRank™: 

ArriVent BioPharma scored higher than 35% of companies evaluated by MarketBeat, and ranked 712th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ArriVent BioPharma has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    ArriVent BioPharma has only been the subject of 4 research reports in the past 90 days.

  • Read more about ArriVent BioPharma's stock forecast and price target.
  • Earnings Growth

    Earnings for ArriVent BioPharma are expected to decrease in the coming year, from ($2.74) to ($3.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ArriVent BioPharma is -5.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ArriVent BioPharma is -5.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ArriVent BioPharma has a P/B Ratio of 2.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about ArriVent BioPharma's valuation and earnings.
  • Percentage of Shares Shorted

    25.85% of the float of ArriVent BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    ArriVent BioPharma has a short interest ratio ("days to cover") of 16.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in ArriVent BioPharma has recently decreased by 12.24%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    ArriVent BioPharma does not currently pay a dividend.

  • Dividend Growth

    ArriVent BioPharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    25.85% of the float of ArriVent BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    ArriVent BioPharma has a short interest ratio ("days to cover") of 16.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in ArriVent BioPharma has recently decreased by 12.24%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    ArriVent BioPharma has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for ArriVent BioPharma this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, ArriVent BioPharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    18.58% of the stock of ArriVent BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 9.48% of the stock of ArriVent BioPharma is held by institutions.

  • Read more about ArriVent BioPharma's insider trading history.
Receive AVBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter.

AVBP Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
Lifesci Capital Has Negative Outlook of AVBP FY2025 Earnings
Analysts Issue Forecasts for AVBP Q2 Earnings
See More Headlines

AVBP Stock Analysis - Frequently Asked Questions

ArriVent BioPharma's stock was trading at $26.64 at the beginning of 2025. Since then, AVBP stock has decreased by 22.1% and is now trading at $20.7550.

ArriVent BioPharma, Inc. (NASDAQ:AVBP) announced its quarterly earnings results on Monday, May, 12th. The company reported ($1.90) earnings per share for the quarter, missing the consensus estimate of ($0.66) by $1.24.

ArriVent BioPharma (AVBP) raised $175 million in an initial public offering on Friday, January 26th 2024. The company issued 9,722,222 shares at a price of $18.00 per share.

Shares of AVBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ArriVent BioPharma investors own include CRISPR Therapeutics (CRSP), Pure Storage (PSTG), Opendoor Technologies (OPEN), Tesla (TSLA), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
5/12/2025
Today
7/06/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AVBP
Previous Symbol
NASDAQ:AVBP
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$40.00
High Stock Price Target
$45.00
Low Stock Price Target
$36.00
Potential Upside/Downside
+92.7%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$80.49 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$7.65 per share
Price / Book
2.71

Miscellaneous

Free Float
27,856,000
Market Cap
$710.03 million
Optionable
N/A
Beta
1.20
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:AVBP) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners